Drugs in the Pipeline Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Drugs in the Pipeline Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued